By the OFFFIELD Editorial Team. Published June 9, 2026. Last updated June 23, 2026.

The short answer: Across large observational studies, cannabis users show lower obesity rates and lower average BMI than non-users, gain weight more slowly over time, and report exercising more, despite the munchies stereotype. Researchers attribute this to how the endocannabinoid system regulates metabolism, appetite, and the reward value of movement. The data is association, not proof of cause, and OFFFIELD products are not weight-loss products.

Key Takeaways

• A national survey of nearly 736,000 adults found current cannabis users were about 31% less likely to be obese than non-users, per the cited study. This is an association, not proof that cannabis causes lower weight.
• The leading mechanism researchers propose is CB1 receptor downregulation, which may shift the endocannabinoid system toward a leaner metabolic set point.
• Cannabis users report being more physically active on use days, and they cite focus and exercise enjoyment as reasons, consistent with the ECS role in movement.
• GLP-1 drugs are effective clinical tools, but studies flag lean-muscle loss, weight rebound after stopping, high cost, and side effects. These are described per the sources, not as advice.
• OFFFIELD does not sell weight-loss products and makes no weight-loss claims. The gummies are designed to support the ECS pathways tied to enjoyable movement.

America is spending hundreds of dollars a month on injectable weight loss drugs.

Roughly one in eight American adults has now used a GLP-1 medication. Ozempic and Wegovy have become a defining pharmaceutical story of the decade: promise and risk packed into a weekly injection, marketed as the answer to a public health crisis that's been building since the 1970s.

Meanwhile, a quieter body of research has been accumulating for years. Peer-reviewed studies across hundreds of thousands of participants consistently report the same association: cannabis users have lower rates of obesity than non-users. They gain less weight over time. And contrary to the lazy stoner stereotype, they report exercising more.

What do the obesity numbers actually show?

Let's start with the data.

A study drawing on a nationally representative sample of nearly 736,000 participants found that current cannabis users were 31 percent less likely to be obese than non-users. Daily users were 32 percent less likely. The relationship held after adjustment for confounders including age, sex, race, income, and smoking status.

The BMI numbers are concrete. Across studies reporting body mass index, the mean BMI of non-users was 27.5 kg/m2, firmly in the overweight range. The mean BMI of cannabis users was 26.0 kg/m2. Among the heaviest users, BMI was reported at 25.5 kg/m2. That's a 2-point difference that, at population scale, represents millions of people.

A prospective 3-year study published in the International Journal of Epidemiology followed participants over time. Everyone gained weight over the study period, but cannabis users gained significantly less. Persistent cannabis users showed attenuated BMI increases compared to never-users, even after controlling for lifestyle variables.

Important framing: these are observational findings. They describe an association, not proof that cannabis causes lower body weight.

Why isn't the munchies paradox actually paradoxical?

The obvious counterargument is appetite. Cannabis increases appetite. The munchies are pharmacologically real, driven by THC's activation of CB1 receptors in the hypothalamus. So how do users end up leaner, on average?

Researchers point to the endocannabinoid system (ECS) itself.

A theoretical paper in Cannabis and Cannabinoid Research proposes a mechanism: chronic cannabis use may trigger lasting downregulation of CB1 receptors. When CB1 receptors are persistently exposed to cannabinoids, the body reduces their density and sensitivity, a standard adaptive response. The authors theorize this is associated with reduced energy storage and increased metabolic rate.

In simpler terms: regular cannabis use may recalibrate the ECS toward a leaner metabolic set point, partially offsetting both the appetite-stimulating effects of acute THC exposure and broader metabolic dysregulation. This remains a proposed mechanism, not settled fact.

A 2024 review in Pharmacology Research & Perspectives described CBD acting as a negative allosteric modulator of CB1 receptors, blocking strong agonist binding, with reported metabolic effects in models that include fat browning, reduced lipid accumulation, and improved insulin sensitivity. THCV, another cannabinoid, showed decreased appetite, increased energy expenditure, and improved glucose tolerance in preclinical models.

The ECS is one of the body's primary regulatory systems for energy homeostasis, appetite, and fat storage. The research frames cannabis as engaging this system rather than circumventing it.

Do cannabis users really exercise more?

Weight and movement are inseparable, which makes the physical activity data worth examining alongside the BMI data.

A federally funded study, covered by Marijuana Moment and consistent with research in the Journal of Cannabis Research, found that people reported being more physically active on days they used cannabis. Not less. More.

Frequent cannabis users reported greater physical activity than non-current users. Light users had higher odds of self-reporting regular exercise. The findings were particularly pronounced among adults over 40 and among non-smokers, and the association was strongest in states with legal recreational access.

When researchers asked cannabis users why they used around exercise, the top responses were helping to focus or concentrate (66%), helping enjoy the exercise experience (65%), and enhancing mind-body connection (65%).

This aligns with what research describes about the ECS and exercise, where anandamide elevation is linked to exercise's mood-elevating effects. Cannabinoids appear to support the same receptor system that makes movement feel rewarding. If cannabis makes exercise more enjoyable, and regular exercise reduces obesity risk, the lower-BMI association starts to make biological sense.

What is the GLP-1 picture really showing?

GLP-1 receptor agonists are effective pharmaceutical tools for significant, rapid weight loss in clinical populations with obesity-related comorbidities. That clinical utility is real.

But the longer the data accumulates, the more complicated the risk-benefit calculus becomes for people using these drugs primarily for cosmetic weight management. The points below are reported per the cited sources.

On muscle loss: Research reported that roughly 40 percent of the weight lost on GLP-1 drugs is lean muscle mass, not fat. When users stop and regain weight, the regained mass is reported to be largely fat, leaving some patients with a worse body composition ratio than before.

On weight rebound: A 2026 review found that most people regain the majority of their lost weight within one to two years of stopping GLP-1 medications.

On cost: GLP-1 medications were reported to run between $349 and $800 per month in the United States, with Americans paying 2 to 4 times more than patients in Europe.

On side effects: Nausea, vomiting, diarrhea, and constipation were reported in roughly 50% of users; gallstone formation in 2 to 4% of clinical trial participants; with rare but serious risks including pancreatitis and acute kidney injury.

None of this makes GLP-1s bad drugs. It makes them powerful interventions with trade-offs, appropriate for clinical weight management under medical supervision.

How should you think about movement and the ECS?

The obesity crisis is real, and the pharmaceutical response is in many ways a good-faith attempt to solve a problem that diet and exercise advice has struggled to crack at population scale.

But the cannabis research points toward a different frame. Rather than suppressing appetite pharmacologically, the open question researchers raise is whether supporting the body's own metabolic regulation system through movement, sleep, and recovery could matter for healthy body weight.

The answer isn't fully written. Cannabis research has been underfunded due to federal prohibition, and the long-term metabolic studies needed to confirm causality have not been done at scale. The current data is association, not intervention. But the direction is consistent: people who use cannabis tend to weigh less, gain weight more slowly, and report exercising more.

OFFFIELD's take

OFFFIELD's High Performance Energy Gummies are formulated for people who already exercise, or want to. To be clear, they are not a weight-loss product and we make no weight-loss claims. The blend of 3mg THC, 10mg CBG, and 40mg CBD is designed to support the ECS pathways tied to enjoyable, focused movement. In a 2026 survey of OFFFIELD subscribers, 96% said they use it every session, 82% train five or more days a week, and 67% are training for a specific race or event. (Survey of OFFFIELD subscribers, 2026. Methodology available on request.)

Recovery happens at night. High Performance Sleep Gummies pair 2mg THC with CBD, CBN, magnesium glycinate, and L-theanine to support deep sleep. The whole picture is on our Science page.

Frequently Asked Questions

Do cannabis users really have lower obesity rates?
In multiple large observational studies, including one of about 736,000 participants, cannabis users showed lower average BMI and lower obesity rates than non-users. These are associations, not proof of cause.

How does cannabis affect body weight if it increases appetite?
The leading hypothesis is CB1 receptor downregulation. Chronic exposure may reduce receptor density and sensitivity, which researchers theorize attenuates energy storage and increases metabolic rate, partially offsetting acute appetite stimulation.

Do cannabis users exercise more or less than non-users?
Research finds cannabis users report being more physically active on use days and more likely to report regular exercise, possibly because cannabinoids support the ECS pathways that make movement feel rewarding.

Is cannabis a safer alternative to Ozempic for weight management?
This is not an appropriate comparison for most people. GLP-1 drugs are prescription medications for clinical obesity. Cannabis is not FDA-approved for weight management, the BMI data is observational, and OFFFIELD makes no weight-loss claims. Consult a healthcare professional about any medication decision.

What cannabinoids are most relevant to metabolism in research?
CBD, CBG, and THCV all show metabolic relevance in peer-reviewed research, though much of it is preclinical. This is not a claim that any product causes weight loss.

A foundation worth building on

The biological mechanisms through which the ECS regulates metabolism, appetite, and the reward value of physical activity are established science. The link to body weight in humans is promising association that deserves more research. Movement made happy means supporting a system that's already working, not replacing it.

Explore High Performance Energy Gummies and dig deeper on our Science page.

---

Related Reading

This post is part of our Sober-Curious cluster. Start with the pillar guide, then explore the related posts:

• Pillar: Sober Curious Summer: Why Active People Are Trading Beer for Low-Dose THC
• Cannabis and Exercise Enjoyment: What the Dose Really Does
• Exercise and the Endocannabinoid System: Why Movement Makes You Happy

---

Sources / References

1. Merrill RM. A National Survey of Marijuana Use Among U.S. Adults According to Obesity Status, 2016-2022. Cannabis and Cannabinoid Research. 2024. Journal
2. Clark TM, Jones JM, Hall AG, et al. Theoretical Explanation for Reduced Body Mass Index and Obesity Rates in Cannabis Users. Cannabis and Cannabinoid Research. 2018. PMC
3. Alshaarawy O, Anthony JC. Are cannabis users less likely to gain weight? Results from a national 3-year prospective study. International Journal of Epidemiology. 2019. PubMed
4. Merrill RM, Ashton-Hwang K, Gallegos L. Association between cannabis use and physical activity in the United States based on legalization and health status. Journal of Cannabis Research. 2024. PMC
5. Kurtov M, Rubinic I, Likic R. The endocannabinoid system in appetite regulation and treatment of obesity. Pharmacology Research & Perspectives. 2024. PMC
6. Study: Cannabis Use Correlated With Lower Rates of Obesity. NORML. 2024. NORML
7. GLP-1 Drugs Deliver Huge Weight Loss but New Research Reveals a Hidden Catch. ScienceDaily. 2025. ScienceDaily
8. Many People Who Come Off GLP-1 Drugs Regain Weight Within 2 Years. CNN. 2026. CNN

---

Legal Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This article is for informational and educational purposes only and is not medical advice. OFFFIELD products are not intended to diagnose, treat, cure, or prevent any disease or medical condition, and are not weight-loss products. The research cited describes associations in observational studies and does not establish cause. Hemp-derived products contain less than 0.3% delta-9 THC in compliance with the 2018 Farm Bill. Consult a healthcare professional before beginning any supplement regimen or making changes to an existing medication plan, including GLP-1 therapies. Must be 21 or older to purchase.